Revive's lead product is in the treatment for acute gout flares, which completed a Phase 2a study in the U.S.
Revive Therapeutics Appoints Tessio Rebello, Ph.D. as Clinical Advisor
Revive Therapeutics Ltd Announces Results for the Three and Six Months Ended December 31, 2015
Revive Therapeutics Announces Issuance of U.S. Patent Related to Bucillamine in the Treatment of Gout
Revive Therapeutics to Present at Noble Capital Markets' Investor Conference
Revive Therapeutics Announces DTC Eligibility of Its Common Shares